Research programme: controlled-release CNS therapeutic - Avadel/unknown
Latest Information Update: 04 Nov 2017
At a glance
- Originator Unknown
- Developer Avadel Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in CNS-disorders in France (PO, Controlled release)
- 03 Jan 2017 Flamel Technologies completed its cross-border merger with Avadel Pharmaceuticals and is now called Avadel Pharmaceuticals
- 17 Oct 2011 Preclinical development is ongoing in France